Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024
NEW YORK, Dec. 17, 2014 /PRNewswire/ -- Report Details
Biosimilar drugs – discover trends and segments with highest potential revenues
Do you want to find sales potentials of biosimilars? Visiongain's updated report gives you revenue predictions for those biological drugs from 2014, helping you stay ahead. For those therapies you find financial data, R&D trends, opportunities and selling prospects.
In that new analysis you get sales forecasts to 2024 at overall world market, therapeutic class, molecule and national level. You also assess trends, technologies and expected products, benefiting your reputation for technological, clinical and commercial insight.
Developments in that industry – see what's possible for those biotech medicines
There you explore what the future holds for biosimilars (follow-on biologics, follow-on protein products). So read on to investigate that industry and hear what future sales it could achieve.
Forecasts and other analyses explain the best financial prospects
In our study you find revenue forecasting to 2024, historical results, growth rates and market shares. There you get quantitative and qualitative analysis, business news and research and development (R&D). You also gain 104 tables, 76 charts and two company interviews.
Many opportunities exist for those competitors of original biological drugs (biologics). You discover segments most likely to prosper. Finding data you need just got easier. There help your research, analyses and plans, increasing your chances of success.
And the following sections show how you benefit from that new analysis.
Predictions for that world market and its submarkets
Along with revenue prediction for the overall world market for biosimilars, our work shows forecasts to 2024 for its individual submarkets:
• Monoclonal antibodies (mAbs) and fusion proteins (FPs) – including rituximab, infliximab, trastuzumab, adalimumab and etanercept segments
• Insulins – inc. submarkets of human insulin and analogues, as well as insulin glargine and insulin lispro
• Erythropoietins (EPO)
• Granulocyte colony-stimulating factors (G-CSF)
• Interferons – inc. alpha and beta segments
• Growth hormones (hGH, somatropin)
• Fertility hormones
That report shows you revenue potentials of those biopharmaceuticals, helping you find chances to develop your business. Also benefit your authority on those treatments.
Our investigation also discusses what stimulates and restrains sales of those subsequent entry biologics. You explore that industry, seeing what products can achieve the most success.
Comparisons of biosimilar drug sales with those of the overall biologics market
You also discover revenues to 2024 for the overall biologics market and its segments. There find how the biosimilars market compares at world level. See how market share can expand.
Our study also divides its forecasting into geographical regions.
National markets for those therapeutic proteins – where will highest sales and growth occur?
Developments worldwide will influence that follow-on biologics market, raising demand for biosimilars in developed and developing countries. See how and where.
Our analyses show you individual revenue forecasts to 2024 for 12 national markets and one regional block:
• United States (US)
• Japan
• European Union (EU) and leading members – Germany, France, UK, Italy and Spain
• BRIC nations – Brazil, Russia, India and China
• South Korea.
There you discover progress and outlooks. You assess the biosimilar industry's future – hear about developments and find their significance. Our work explains, exploring issues.
Forces affecting that biopharmaceutical industry and market
That new report discusses issues and events affecting the industry and market from 2014, including these developments:
• Considerations for developing biosimilars –
Read the full report: http://www.reportlinker.com/p02571393-summary/view-report.html
About Reportlinker
ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - instantly, in one place.
http://www.reportlinker.com
_________________________
Contact Clare: [email protected]
US: (339)-368-6001
Intl: +1 339-368-6001
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/biosimilars-and-follow-on-biologics-world-industry-and-market-prospects-2014-2024-300011464.html
SOURCE Reportlinker
Related Links
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article